Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 01, 2005. The report is a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) held through various employee benefit and retirement plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details and plan valuations rather than consolidated financial performance.
- Share Price (US Retirement Savings Plan): $44.81 per share (Jan 28, 2005), $44.54 average (Jan 27, 2005), and $45.05 average (Jan 28, 2005).
- Share Price (UK Bonus Investment Plan): £11.71 per share (Jan 27, 2005).
- Plan Holdings: The US Retirement Savings Plan held between 18,466,108 and 18,554,433 Ordinary Share ADRs during the reporting window.
Material Changes
The filing details specific movements in share ownership within employee trusts and retirement plans affecting directors:
- GlaxoSmithKline Employee Trust: Transferred 4,828 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on January 28, 2005.
- SmithKline Beecham Employee Benefit Trust: Sold 1,806 Ordinary Shares on behalf of a participant on January 27, 2005, and transferred 2,588 Ordinary Shares to a participant in the Bonus Investment Plan.
- US Retirement Savings Plan: Notional allocations for directors Dr. J-P Garnier and Dr. T Yamada increased due to fund re-valuation. The total fund holdings fluctuated between 18,466,108 and 18,554,433 ADRs due to market movements.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance report regarding director share interests and does not contain forward-looking statements or risk assessments.
Investor Verification Checklist
- Verify the total number of shares held by directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe across all employee trusts and retirement plans.
- Confirm the impact of the reported share transfers and sales on the directors' total beneficial ownership percentages.
- Review the valuation methodology for the notional investment in the US Retirement Savings Plan to understand the basis for the ADR allocation changes.
- Check subsequent filings for any further changes in director interests or updates to the employee benefit trust structures.